COBIO has been jointly invested by domestic listed company and world-renowned enterprise

A strategic investment agreement has been signed by "COBIO Smart Healthcare Technology Co., Ltd", "ARKRAY, Inc." and "Shenzhen YHLO Biotech. Co., Ltd" recently. Under the framework, COBIO will get the joint investment by ARKRAY and YHLO for the expansion of company production scale and development of cutting-edge technology. At the same time, the advanced management experience and perfect global marketing system of ARKRAY and YHLO will facilitate COBIO to achieve further improvement of product quality and rapidly expansion the global market.

ARKRAY, Inc. was founded in 1960 and headquartered in Kyoto, Japan. As the inventor of automatic urine analyzer and hemoglobin A1c analyzer, ARKRAY has 7 factories and dozens of subsidiaries world.

Founded in 2008 and headquartered in Shenzhen, YHLO is a listed company and a leading IVD enterprise in China. Its main business covers the R&D, production and sales of diagnostic instruments and reagents for chemiluminescence and immunofluorescence methodologies.

Shanghai-based COBIO was founded in 2012, taking the lead in combining artificial intelligence, machine vision, internet and traditional medical diagnosis technology. After years of independent R&D and joint innovation, a serial of products of automatic urine sediment analyzer developed by the company are widely used in various types of medical and animal laboratories. In 2021, COBIO has reached a strategic cooperation with Roche Diagnostics, Siemens Healthineers and ARKRAY, Inc. respectively, aiming to jointly develop the domestic and global urinalysis market.